JP2012504628A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504628A5 JP2012504628A5 JP2011530150A JP2011530150A JP2012504628A5 JP 2012504628 A5 JP2012504628 A5 JP 2012504628A5 JP 2011530150 A JP2011530150 A JP 2011530150A JP 2011530150 A JP2011530150 A JP 2011530150A JP 2012504628 A5 JP2012504628 A5 JP 2012504628A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- compound
- optionally
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- SVFIZNZDTQAIQG-UHFFFAOYSA-N 2-amino-6-(6-aminopyridin-3-yl)-4-methyl-8-(oxan-4-yl)pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1C(C=2C=NC(N)=CC=2)=CC=2C(C)=NC(N)=NC=2N1C1CCOCC1 SVFIZNZDTQAIQG-UHFFFAOYSA-N 0.000 claims description 2
- PPDYHMXJTNTNFD-LLVKDONJSA-N 2-amino-6-(6-aminopyridin-3-yl)-4-methyl-8-[(3r)-oxolan-3-yl]pyrido[2,3-d]pyrimidin-7-one Chemical compound O=C1C(C=2C=NC(N)=CC=2)=CC=2C(C)=NC(N)=NC=2N1[C@@H]1CCOC1 PPDYHMXJTNTNFD-LLVKDONJSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 0 Cc1nc(N*)nc(N2[C@]3COCC3)c1C=C(c1cnc(*)cc1)C2=O Chemical compound Cc1nc(N*)nc(N2[C@]3COCC3)c1C=C(c1cnc(*)cc1)C2=O 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19476108P | 2008-09-30 | 2008-09-30 | |
| US61/194,761 | 2008-09-30 | ||
| PCT/US2009/058881 WO2010039740A1 (en) | 2008-09-30 | 2009-09-29 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504628A JP2012504628A (ja) | 2012-02-23 |
| JP2012504628A5 true JP2012504628A5 (enExample) | 2012-11-15 |
Family
ID=41572575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530150A Pending JP2012504628A (ja) | 2008-09-30 | 2009-09-29 | ＰＩ３ＫαおよびｍＴＯＲのピリドピリミジノン阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8101622B2 (enExample) |
| EP (1) | EP2350070A1 (enExample) |
| JP (1) | JP2012504628A (enExample) |
| AR (1) | AR073524A1 (enExample) |
| PA (1) | PA8843901A1 (enExample) |
| TW (1) | TW201018685A (enExample) |
| UY (1) | UY32153A (enExample) |
| WO (1) | WO2010039740A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140105621A (ko) * | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | ＰＩ３Ｋα의 피리도피리미디논 억제제 |
| WO2007044729A2 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| ATE539752T1 (de) | 2006-08-16 | 2012-01-15 | Exelixis Inc | Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung |
| ATE514695T1 (de) | 2006-09-15 | 2011-07-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren |
| CA2683641C (en) * | 2007-04-10 | 2016-08-16 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| AU2008239655B2 (en) * | 2007-04-11 | 2013-06-20 | Exelixis, Inc. | Pyrido (2, 3-d) pyrimidin-7-one compounds as inhibitors of PI3k-alpha for the treatment of cancer |
| WO2011100319A1 (en) | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
| CA2812089C (en) | 2010-09-14 | 2020-02-18 | Exelixis Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| CA2828483A1 (en) * | 2011-02-23 | 2012-11-01 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| KR20140040726A (ko) * | 2011-04-29 | 2014-04-03 | 엑셀리시스, 인코포레이티드 | PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법 |
| PE20141794A1 (es) | 2011-11-01 | 2014-12-17 | Exelixis Inc | N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas |
| EP3266455B1 (en) | 2015-03-06 | 2020-12-30 | Korea Advanced Institute of Science and Technology | Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| WO2020247496A1 (en) | 2019-06-04 | 2020-12-10 | Arcus Biosciences, Inc. | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |
| CN114901664B (zh) * | 2020-01-10 | 2024-07-02 | 南京再明医药有限公司 | 吡啶酮化合物及应用 |
| US20230165864A1 (en) * | 2020-04-30 | 2023-06-01 | Guangzhou Joyo Pharmatech Co., Ltd | Application of heterocyclic compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
| AU1808601A (en) | 2000-01-27 | 2001-08-07 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| DZ3308A1 (fr) | 2000-03-06 | 2001-09-27 | Warner Lambert Co | Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines |
| CN1186324C (zh) | 2000-04-27 | 2005-01-26 | 山之内制药株式会社 | 稠合杂芳基衍生物 |
| MXPA03007623A (es) | 2001-02-26 | 2003-12-04 | Tanabe Seiyaku Co | Derivado de piridopirimidina o naftiridina. |
| WO2003000270A1 (en) * | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidones and uses thereof |
| US7019002B2 (en) | 2001-12-11 | 2006-03-28 | Pharmacia & Upjohn, S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
| EP1499320B1 (en) | 2002-04-19 | 2007-08-22 | Smithkline Beecham Corporation | Novel compounds |
| US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
| JP2004083587A (ja) | 2002-08-06 | 2004-03-18 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| WO2004089930A1 (en) | 2003-04-02 | 2004-10-21 | Imclone Systems Incorporated | 4-fluoroquinolone derivatives and their use as kinase inhibitors |
| US20070053831A1 (en) | 2003-05-20 | 2007-03-08 | Barrio Jorge R | Methods for binding agents to b-amyloid plaques |
| CA2555724A1 (en) | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| US20080255162A1 (en) * | 2004-05-04 | 2008-10-16 | Warner-Lambert Company Llc | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents |
| WO2006065703A1 (en) | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
| KR20140105621A (ko) * | 2005-10-07 | 2014-09-01 | 엑셀리시스, 인코포레이티드 | ＰＩ３Ｋα의 피리도피리미디논 억제제 |
| ATE514695T1 (de) * | 2006-09-15 | 2011-07-15 | Pfizer Prod Inc | Pyrido(2,3-d)pyrimidinonverbindungen und ihre verwendung als pi3-inhibitoren |
| BRPI0810175A2 (pt) * | 2007-04-11 | 2014-12-30 | Exelixis Inc | Inibidores pirididopirinidinona de p13k alfa |
-
2009
- 2009-09-29 PA PA20098843901A patent/PA8843901A1/es unknown
- 2009-09-29 WO PCT/US2009/058881 patent/WO2010039740A1/en not_active Ceased
- 2009-09-29 TW TW098133017A patent/TW201018685A/zh unknown
- 2009-09-29 JP JP2011530150A patent/JP2012504628A/ja active Pending
- 2009-09-29 US US12/569,760 patent/US8101622B2/en not_active Expired - Fee Related
- 2009-09-29 AR ARP090103759A patent/AR073524A1/es not_active Application Discontinuation
- 2009-09-29 UY UY0001032153A patent/UY32153A/es not_active Application Discontinuation
- 2009-09-29 EP EP09737495A patent/EP2350070A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504628A5 (enExample) | ||
| US11723908B2 (en) | Quinazoline derivatives as antitumor agents | |
| US9550738B2 (en) | Bicyclic compounds as kinases inhibitors | |
| KR101413392B1 (ko) | 단백질 키나제 억제제로서의 화합물 및 조성물 | |
| JP6139782B2 (ja) | 置換ピラゾロピリミジン化合物、及びその薬学的に許容される塩、並びにこれらの溶媒和物、立体異性体、及び互変異性体、並びにこれらを含む医薬組成物 | |
| AU2016245864B2 (en) | Substituted quinazoline compounds and methods of use thereof | |
| JP2022050628A (ja) | 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法 | |
| TW202333714A (zh) | 包含喹唑啉化合物之醫藥組成物 | |
| CN113677346A (zh) | 周期蛋白依赖性激酶7(cdk7)的抑制剂 | |
| KR20200010306A (ko) | Kras의 공유적 억제제 | |
| JP2013544807A5 (enExample) | ||
| JP2011519941A5 (enExample) | ||
| JP2013522292A5 (enExample) | ||
| KR20170049604A (ko) | Bub1 억제제로서의 벤질 치환된 인다졸 | |
| JP2008535902A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| WO2025045141A1 (en) | Kras inhibitors and uses thereof | |
| CN104203242A (zh) | 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂 | |
| WO2016168014A1 (en) | Targeted treatment of leiomyosarcoma | |
| CA2974788A1 (en) | A 2-pyrimidinyl substituted pyridinyl heterocyclic compound and a pharmaceutical composition comprising the same | |
| JP2018504449A5 (enExample) | ||
| EP3052100A2 (en) | Small molecule securinine and norsecurinine analogs and their use in cancers inflammatory diseases and infections | |
| ES2709003T3 (es) | Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico | |
| JPWO2019214634A5 (enExample) | ||
| JP2009533336A (ja) | テロメラーゼ阻害剤 |